Clinical Trials Logo

Congenital Malformations clinical trials

View clinical trials related to Congenital Malformations.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03831035 Completed - Intensive Care Unit Clinical Trials

Fast Exome for Diagnosis of Congenital Conditions in Infants Under 12 Months of Age Hospitalized in Intensive Care Unit

REUNIR
Start date: April 8, 2019
Phase:
Study type: Observational

An early diagnosis of congenital malformations and suspected genetic conditions in critically ill infants is essential to perform specific adapted care, prevention, and give proper genetic counseling. However, etiologies are various and each of them is individually very rare. Thanks to next-generation sequencing technologies, diagnosis time frames have drastically decreased and the investigators have observed an increase in diagnosis yields. This study aims to evaluate the feasibility of fast trio exome sequencing (less than 16 days between informed consent signature and the consultation for results to the parents) in infants under the age of 12 months hospitalized in Intensive Care Unit (ICU).

NCT ID: NCT02985385 Completed - Clinical trials for Congenital Malformations

Lethal Congenital Malformations: Palliative Therapy From An Islamic Point of View

LCM
Start date: June 2001
Phase: N/A
Study type: Observational

To prove that palliative therapy can be practised for congenital lethal malformations within the Islamic Code of Ethics. After defining lethal malformation no respiratory support is offered and newborns are provided with compassionate care.

NCT ID: NCT02483702 Completed - Clinical trials for Graft Versus Host Disease

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

Start date: August 2015
Phase: N/A
Study type: Interventional

Blood transfusions are required for patients undergoing a craniosynostosis repair due to the significant amount of blood loss. Irradiated or non-irradiated transfusions have many risks involved including elevated potassium levels and graft versus host disease (TA-GVHD). Irradiated blood is able to destroy the leukocytes responsible for TA-GVHD, but it adversely causes elevated extracellular potassium due to hemolysis of the RBC's. When this blood is transfused, it may introduce too much extracellular potassium (> 6.5 meq/L) into the patient causing interference with the heart's conduction system significantly increasing the risk for hemodynamic changes, cardiac arrhythmias, and cardiac arrest. Hyperkalemia from rapid transfusions occurs much more frequently than TA-GVHD; however, both complications are under-reported. The study aims to evaluate the risk of irradiated versus non-irradiated blood in patients under the age of 6 months undergoing a craniosynostosis repair. This will be done by comparing the levels of extracellular potassium pre-transfusion, during transfusion, immediately after transfusion, and 30 minutes after the completion of transfusion. The investigators hypothesize that the patients who receive irradiated blood will have an increased extracellular potassium level compared to those who receive non-irradiated blood.